Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Apple Turns 50: From Garage Startup to AI Crossroads 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
OXFORD, United Kingdom, Dec. 13, 2016 -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be announcing its financial results for the third quarter and nine months ended 31 October 2016 on Thursday, 15 December 2016.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease DMD and the infectious disease Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
| Summit Therapeutics Glyn Edwards / Richard Pye (UK office) Erik Ostrowski / Michelle Avery (US office) | Tel: +44 (0)1235 443 951 +1 617 225 4455 |
| Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Tony Rawlinson | Tel: +44 (0)20 7213 0880 |
| N+1 Singer (Broker) Aubrey Powell / Jen Boorer | Tel: +44 (0)20 7496 3000 |
| MacDougall Biomedical Communications (US media contact) Chris Erdman / Karen Sharma | Tel: +1 781 235 3060 [email protected] / [email protected] |
| Consilium Strategic Communications (Financial public relations, UK) Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / Lindsey Neville | Tel: +44 (0)20 3709 5700 [email protected] |
